Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The continued global burden of malaria can in part be attributed to a complex lifecycle, with both human hosts and mosquito vectors serving as transmission reservoirs. In preclinical models of vaccine-induced immunity, antibodies to parasite sexual-stage antigens, ingested in the mosquito blood meal, can inhibit parasite survival in the insect midgut as judged by ex vivo functional studies such as the membrane feeding assay. In an era of renewed political momentum for malaria elimination and eradication campaigns, such observations have fueled support for the development and implementation of so-called transmission-blocking vaccines. While leading candidates are being evaluated using a variety of promising vaccine platforms, the field is also beginning to capitalize on global '-omics' data for the rational genome-based selection and unbiased characterization of parasite and mosquito proteins to expand the candidate list. This review covers the progress and prospects of these recent developments.

Original publication

DOI

10.1586/14760584.2015.993383

Type

Journal article

Journal

Expert Rev Vaccines

Publication Date

05/2015

Volume

14

Pages

653 - 680

Keywords

Plasmodium falciparum, genome, malaria, membrane feeding assay, transmission-blocking vaccine, Animals, Antibodies, Protozoan, Culicidae, Disease Transmission, Infectious, Drug Discovery, Humans, Malaria, Plasmodium, Vaccines